Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV-and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)

David L. Wyles*, Minhee Kang, Roy M. Matining, Robert L. Murphy, Marion G. Peters

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Final results from the long-term Viral Hepatitis C Infection Long-term Cohort Study (V-HICS) found low rates of hepatitis C virus (HCV) recurrence after direct-acting antiviral therapy in both HCV/human immunodeficiency virus (HIV)-coinfected (0.67/100 person-years) and HCV-infected (0.2/100 person-years) groups with >500 person-years of follow-up. Confirmed reinfections were in participants with HIV who reported high-risk behaviors.

Original languageEnglish (US)
Article numberofab511
JournalOpen Forum Infectious Diseases
Volume8
Issue number12
DOIs
StatePublished - Dec 1 2021

Keywords

  • HIV
  • direct-acting antivirals
  • hepatitis C
  • recurrence

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV-and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)'. Together they form a unique fingerprint.

Cite this